ArticleScientific reports2026
Fengycin deficiency in Bacillus subtilis Pfen-1 increases antagonism and reveals a non-functional role against Sclerotinia sclerotiorum.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Bacillus subtilis is a widely used agricultural probiotic for plant disease control. We previously reported the novel B. subtilis HF1, which produces abundant fengycin and surfactin lipopeptide homologues. This study investigates fengycin's functions in HF1. Surprisingly, the fengycin-deficient mutant Pfen-1 exhibited enhanced antagonism against Sclerotinia sclerotiorum. Using Pfen-1 as an ideal tool to probe fengycin function, we tested lipopeptide extracts against 20 plant pathogenic fungi. Results indicated that fengycin is the primary antifungal lipopeptide in HF1 against most fungi but not against S. sclerotiorum. We elucidated the specific, efficient biocontrol mechanism of Pfen-1 against S. sclerotiorum in rapeseed. Pfen-1 consistently showed higher activity than HF1 in some key enzymes including cellulase, proteinase, chitinase, amylase, and β-1,3-glucanase - across different culture stages, a finding corroborated by transcriptome data. Additionally, Pfen-1 significantly boosted defensive enzyme activity in rapeseed, contributing to its excellent biocontrol efficacy. This work provides new insights into fengycin's functions and offers a promising mutant strain for developing more effective agents against S. sclerotiorum in rapeseed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.